M&A Deal Summary

Pfizer Acquires Baxter International - Marketed Vaccines

On July 30, 2014, Pfizer acquired life science company Baxter International - Marketed Vaccines from Baxter International for 635M USD

Acquisition Highlights
  • This is Pfizer’s 19th transaction in the Life Science sector.
  • This is Pfizer’s 15th largest (disclosed) transaction.
  • This is Pfizer’s 1st transaction in Austria.

M&A Deal Summary
Date 2014-07-30
Target Baxter International - Marketed Vaccines
Sector Life Science
Buyer(s) Pfizer
Sellers(s) Baxter International
Deal Type Divestiture
Deal Value 635M USD

Target

Baxter International - Marketed Vaccines

Orth, Austria
Baxter’s portfolio of marketed vaccines consists of NeisVac-C and FSME-IMMUN/TicoVac. NeisVac-C is a vaccine that helps protect against meningitis caused by group C meningococcal meningitis (MenC).

Search 192,611 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Pfizer

New York, New York, United States

website

Category Company
Founded 1849
Sector Life Science
Employees8,300
Revenue 58.5B USD (2023)
DESCRIPTION
Pfizer office in Lake Forest, Illinois.
Pfizer office in Lake Forest, Illinois.

Pfizer is a global pharmaceutical company that is involved in the discovery, development, manufacture, and marketing of a wide range of healthcare products, including medicines and vaccines. The company's portfolio includes treatments across a broad spectrum of areas such as oncology, cardiology, neurology, and infectious diseases, among others. Pfizer was founded in 1849 and is based in New York, New York.

DEAL STATS #
Overall 22 of 43
Sector (Life Science) 19 of 39
Type (Divestiture) 1 of 5
Country (Austria) 1 of 1
Year (2014) 2 of 2
Size (of disclosed) 15 of 21
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2014-07-16 InnoPharma

Piscataway Township, New Jersey, United States

InnoPharma is a sterile product development company, focused on developing complex generic and innovative specialty pharmaceutical products in injectable and ophthalmic dosage forms. The Company has a broad portfolio of products under development, with formulations including solutions, suspension, lyophilized, emulsions, liposomes, micelles and lipid complexes. InnoPharma’s pipeline includes small molecules with solubility and stability challenges, as well as difficult to produce and characterize polypeptides and carbohydrates.

Buy $370M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2015-01-07 Redvax

Zurich, Switzerland

Redvax is a Swiss, preclinical biopharmaceutical company based in Zurich. Redvax has produced a preclinical human cytomegalovirus (CMV) vaccine candidate, as well as intellectual property and a technology platform related to a second, undisclosed vaccine program.

Buy -

Seller(S) 1

SELLER

Baxter International

Deerfield, Illinois, United States

website

Category Company
Founded 1931
Sector Medical Products
Employees60,000
Revenue 15.1B USD (2022)
DESCRIPTION
Entrance to Baxter International's corporate headquarters in Deerfield, Illinois.
Entrance to Baxter International's corporate headquarters in Deerfield, Illinois.

Baxter International develops, manufactures and markets drugs and medical products for people with a variety of medical conditions. Baxter's operations are comprised of the BioScience and Medical Products segments. The BioScience business processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; biosurgery products; and select vaccines. The Medical Products business manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, and inhalation anesthetics. The business also provides products and services related to pharmacy compounding, drug formulation and packaging technologies. In addition, the Medical Products business provides products and services to treat end-stage renal disease, or irreversible kidney failure. Baxter International was founded in 1931 and is based in Deerfield, Illinois.

DEAL STATS #
Overall 4 of 6
Sector (Life Science) 2 of 4
Type (Divestiture) 4 of 5
Country (Austria) 1 of 1
Year (2014) 1 of 1
Size (of disclosed) 2 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2014-04-02 Chatham Therapeutics

United States

Chatham Therapeutics, LLC (Chatham) is a privately held clinical development-stage biotechnology company engaged in the development of novel, gene therapy-mediated treatments for hemophilia. The company is currently engaged in gene therapy-based therapeutic programs for both hemophilia A and B.

Buy $70M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2015-03-04 SuppreMol

Planegg, Germany

SuppreMol GmbH is a biopharmaceutical company developing novel therapeutics for the treatment of autoimmune and allergic diseases.

Buy €200M
Mergr

Product

Company

Legal